Only for Retts and Fragile X. I would think this is a good outcome to avoid clashes and give Acadia optimum incentive to push forward on those two indications. Doesn't impact the 4 indications in Phase 2 trials or all the other potential indications
Acadia got Rof Trofenitde AND Global rights for NNZ-2591 for RETT/Fragile X, page-7
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.806B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1002 | $14.05 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 16726 | 8 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |